Analysts have raised their price target for Shilpa Medicare marginally from ₹514.25 to ₹514.50, citing a slightly improved profit margin outlook and steady revenue growth expectations.
What's in the News
- Shilpa Medicare secured regulatory approval from India's Central Drugs Standard Control Organization for Nor Ursodeoxycholic Acid (NorUDCA) Tablets 500 mg. This marks the first approved therapy for NAFLD, with rapid commercialization planned in India and globally (Key Developments).
- Alveolus Bio announced a strategic financing round led by Shilpa Medicare. Shilpa Biologics will be its exclusive global development and manufacturing partner for advancing inhaled therapeutics for diseases such as COPD and Pulmonary Fibrosis (Key Developments).
- A 2:1 stock split or significant stock dividend was announced and is scheduled for October 3, 2025 (Key Developments).
- A board meeting is set for August 13, 2025, to discuss unaudited financial results, AGM scheduling, board member reappointments, a bonus share issue, and other matters (Key Developments).
- A special or extraordinary shareholders meeting is scheduled via postal ballot in India on November 8, 2025 (Key Developments).
Valuation Changes
- Consensus Analyst Price Target has increased marginally from ₹514.25 to ₹514.50.
- Discount Rate remains unchanged at 12.73%.
- Revenue Growth estimate has edged down slightly, from 23.55% to 23.53%.
- Net Profit Margin projection has risen modestly from 24.95% to 25.39%.
- Future P/E ratio forecast has decreased slightly from 23.09x to 22.71x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.